BioSpace News Archive

Clorox Healthcare Canada sets sights on helping to reduce hospital-borne infections and improve patient outcomes

Clorox Healthcare Canada’s innovative array of disinfecting solutions are helping healthcare professionals in leading the fight against emerging hospital-borne infections, safeguarding patients in the places where they’re most vulnerable.

February 28, 2018

·

3 min read

Pharm Country

Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions

“Obtaining preferred coverage of both ARYMO ER and SPRIX Nasal Spray is important to ensure access to our products for healthcare providers and for the individuals covered by this large health plan,” said Patrick Shea, chief commercial officer of Egalet.

February 28, 2018

·

24 min read

Job Trends

Inscripta Raises $55.5 Million to Advance Gene-Editing Technology

Investment will grow company’s expert team, accelerate development and commercialization of gene-editing tools -- including enzymes, reagents, instrumentation, and software.

February 28, 2018

·

3 min read

Biotech Beach

Steven Prewitt Skull Base Disease Foundation Presents $600,000 Donation to the North American Skull Base Society

The event was held at the Loews Coronado Bay Resort in Coronado, California.

February 28, 2018

·

2 min read

Valeant Announces Redemption Of Remaining $71 Million Aggregate Principal Amount Of Its Outstanding 7.00% Senior Unsecured Notes Due 2020

“Addressing our debt remains a priority for us as we continue to transform Valeant,” said Joseph C. Papa, chairman and CEO, Valeant.

February 28, 2018

·

3 min read

Deals

Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE from Synergy Pharmaceuticals

TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.

February 28, 2018

·

10 min read

Drug Development

Acceleron Announces Publication of ACE-083 Phase 1 Trial Results in Muscle & Nerve

CE-083 treatment generated dose-dependent mean total muscle volume increases of up to 14.5% in the rectus femoris and 8.9% in the tibialis anterior three weeks after the last dose.

February 28, 2018

·

5 min read

Drug Development

MabVax Therapeutics Reports Positive Safety Results from Initial Cohort of MVT-1075 Radioimmunotherapy Phase 1 Trial for the Treatment of Pancreatic, Colon and Lung Cancers

MabVax Therapeutics Holdings, Inc announced today positive interim results from the initial cohort of the Phase 1 clinical trial evaluating the Company’s new human antibody-based radioimmunotherapy (“RIT”) product MVT-1075 for the treatment of pancreatic, colon and lung cancer.

February 28, 2018

·

6 min read

Business

Second Genome Strengthens R&D Program in Immuno-Oncology with Four Academic Collaborations

Collaborations with John Theurer Cancer Center of Hackensack Meridian Health, Stanford Cancer Institute, Ruprecht-Karls-University Heidelberg and Roswell Park Comprehensive Cancer Center to further understand the influence of gut microbiota on patient response to cancer immunotherapies

February 28, 2018

·

4 min read

Business

LivaNova Reports Fourth Quarter and Full-Year 2017 Results

For the fourth quarter of 2017, worldwide sales from continuing operations were $278.4 million, an increase of 11.5 percent on a reported basis and an increase of 8.1 percent on a constant currency basis, as compared to the same quarter of the previous year.

February 28, 2018

·

35 min read